www.clinicalleader.com Open in urlscan Pro
20.185.12.70  Public Scan

Submitted URL: http://nl.clinicalleader.com/dc/6r9ayGBvBoEwsn5nbtZJ3md-NVLWlK2A9_yJW60spuo7MdvgF9h4TD1CxM9lLluzMq3AEQlwm6tKG4JO5z6Op1KzQmSvk...
Effective URL: https://www.clinicalleader.com/doc/weekly-newsletter-schedule-0001?vm_tId=2588552&vm_nId=84585&user=d0fcfd18-077c-4792-92e1-541...
Submission: On May 28 via api from US — Scanned from DE

Form analysis 1 forms found in the DOM

GET /search

<form method="get" class="form-inline nav-search pr-0" action="/search">
  <input class="form-control-sm" name="keyword" type="search" maxlength="250" placeholder="Search" aria-label="Search">
  <button type="submit" class="btn-sm btn-dark">
    <i class="fas fa-search fa-sm"></i>
  </button>
</form>

Text Content

Get more clinical research insight with our FREE newsletter sign me up

Log In or Subscribe
Trial Design Partnering Clinical Technologies Regulatory Market Research
Find A Partner
CRO Services (Phase I-III) Clinical Trial Software and Services Consulting &
Regulatory Partners Patient & Site Solutions
Events
Clinical Leader Live Clinical Leader Solutions Expo




CLINICAL LEADER THEMED NEWSLETTERS: PERSONALIZE YOUR EXPERIENCE



Since 2011, our Monday/Wednesday editorial newsletters have been an effective
means of keeping biopharma professionals up to speed with the latest
developments and innovations in the clinical research and development industry.
These newsletters have always covered a broad range of trial-related topics,
from study design to patient recruitment to data management, just to name a few.

To help our readers accomplish their goals and solve their biggest challenges in
clinical research, we wanted to develop and deliver more of the content they
want and make it easier for them to find and access it.

To personalize the reader experience, the Clinical Leader team solicited reader
feedback to learn their theme preferences and topic needs. Based on that
feedback, we decided to split our two expansive weekly newsletters into five
slimmed-down, topic-specific daily newsletters. Here is the new schedule for
these themed newsletters:



Sign up today to start receiving newsletters on topics of interest to you. If
you are already a Clinical Leader subscriber, you can update your topic
preferences by visiting your profile page. 


WHAT ARE THE TOPIC PREFERENCES OF OTHER CLINICAL LEADER READERS?

Check out the selections of a few hand-picked readers:



 

 

 

 

 

 





  Free Clinical Leader Newsletter



YOU MAY ALSO LIKE...

 * 03.27.21 -- FOUR STEPS SPONSORS CAN TAKE TO INCREASE PATIENT RECRUITMENT
   
   03/27/21 Clinical Leader Newsletter

 * SAREPTA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND FOR THE COMPANY’S PPMO
   EXON 51 CANDIDATE, SRP-5051
   
   Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
   biopharmaceutical company focused on the discovery and development of
   precision genetic medicine to treat rare neuromuscular diseases,...

 * POINT OF CARE SOLUTIONS FOR PHARMACEUTICAL CLINICAL TRIALS
   
   Blinded Diagnostics is a contract service organization specializing in same
   day lab test results using point-of-care diagnostic platforms to optimize
   patient enrollment testing, blinded studies,...

 * FDA LIFTS HEAT BIOLOGICS PARTIAL CLINICAL HOLD
   
   Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company
   developing novel therapies that activate a patient’s immune system against
   cancer, announced that the U.S.

 * SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL
   TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY
   
   Solid Biosciences Inc. today announced it has received notification from the
   U.S. Food and Drug Administration (FDA) that IGNITE DMD, its Phase I/II
   clinical trial for SGT-001 microdystrophin gene...

 * LILLY/ENTOS DEAL REINFORCES THE SIGNIFICANCE OF DELIVERY MECHANISMS FOR
   NUCLEIC ACID-BASED THERAPIES

 * PUSHING BEYOND THE STATUS QUO IN TRIAL OVERSIGHT

 * TIGENIX ANNOUNCES SIX-MONTH PHASE I/II RESULTS OF ALLOCSC-01 IN ACUTE
   MYOCARDIAL INFARCTION

 * CLINICAL PRACTICE IS AHEAD OF CLINICAL TRIALS WITH TECHNOLOGY USE: EMR VS.
   EPRO

 * HEXOSKIN: CLOTHING THAT RECORDS MEDICAL DATA?

 * AN INTRODUCTION TO APPLICATIONS OF ADAPTIVE DESIGN

 * RESULTS FROM PHASE 2 EXPLORATORY CLINICAL STUDY SUPPORT CONTINUED DEVELOPMENT
   OF GANAXOLONE IN FRAGILE X SYNDROME





This website uses cookies to ensure you get the best experience on our website.
Learn more
Got it!

PARTNER WITH US

 * Request More Information
 * Our Partners

SUBSCRIBE

 * Newsletter
 * Follow Us on LinkedIn

LIFE SCIENCE CONNECT

 * Bioprocess Online
 * Biosimilar Development
 * Cell & Gene
 * Drug Discovery
 * Laboratory Network
 * Life Science Leader Magazine
 * Med Device Online
 * Outsourced Pharma
 * Pharmaceutical Online

EDITORIAL

 * Archived Newsletters
 * Article Reprints
 * Editorial Submission Guidelines
 * Editorial Advisory Board
 * The Expert Network

EVENTS

 * CMO Leadership Awards
 * CRO Leadership Awards

LEARN MORE

 * About Us
 * Contact Us
 * Work For Us


Copyright © 1996-2024 VertMarkets, Inc. All Rights Reserved. Terms of Use.
Privacy Statement. Subscriber Request Form. Don't sell my information
×